P10 INC-A (PX)       9.87  +0.27 (+2.81%)

9.87  +0.27 (+2.81%)

US69376K1060 - Common Stock - After market: 9.87 0 (0%)


Fundamental Rating

4

Overall PX gets a fundamental rating of 4 out of 10. We evaluated PX against 201 industry peers in the Capital Markets industry. PX has a bad profitability rating. Also its financial health evaluation is rather negative. PX is not priced too expensively while it is growing strongly. Keep and eye on this one!




Profitability

Profitability Rating

2

PX's Return On Assets of 3.53% is in line with the rest of the industry. The industry average Return On Assets is 4.07%.
The Piotroski-F score of PX is 6.00. This is a neutral score and indicates average health and profitability for PX.

PX has a Return On Equity of 7.43%. This is below the industry average of 10.75%.
PX has a Profit Margin of 14.72%. This is below the industry average of 18.83%.
VS Industry

ROA (3.53%) VS Industry: 47% outperformed.

0.03
49.12

ROE (7.43%) VS Industry: 33% outperformed.

0.25
232.92

Profit Margin (14.72%) VS Industry: 35% outperformed.

0.36
128.34

Valuation

Valuation Rating

4

With a Forward Price/Earnings Ratio of 10.40, the valuation of PX can be described as very reasonable.
The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a Price/Earnings Ratio of 12.34, PX is valued correctly.
When comparing the current price to the book value of PX, we can conclude it is valued correctly. It is trading at 2.94 times its book value.

PX's Price/Earning Ratio is slightly more expensive than the industry average, which is at 10.40.
When comparing the price book ratio of PX to the average industry price book ratio of 1.09, PX is valued more expensive than its industry peers. 80% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of PX to the average industry ratio of 10.26, PX is valued more expensive than its industry peers.
VS Industry

Price/Earnings (12.34) VS Industry: 38% outperformed.

575.29
0.10

Price/Book (2.94) VS Industry: 20% outperformed.

42.18
0.07

Enterprise Value/ EBITDA (19.68) VS Industry: 26% outperformed.

151.48
0.71

Growth

Growth Rating

7

PX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.26%, which is quite impressive.
Measured over the past 5 years, PX shows a very strong growth in Earnings Per Share. The EPS has been growing by 88.94% on average per year.
The Earnings Per Share is expected to grow by 19.93% on average over the next 5 years. This is quite good.
The Revenue has grown by 31.77% in the past year. This is a very strong growth!

The Revenue has been growing by 115.08% on average over the past 5 years. This is a very strong growth!
PX is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 19.98% yearly.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS88.94% 22.13% 86.26% 18.63% 19.93% N/A N/A
Revenue115.08% 64.08% 31.77% 21.17% 19.98% N/A N/A

Health

Health Rating

3

The Altman-Z score of PX is much better than the industry average of 0.90.
The Debt to Equity ratio of PX is in line with the industry averages.
The Piotroski-F score of PX is 6.00. This is a neutral score and indicates average health and profitability for PX.
A Current Ratio of 0.82 indicates that PX may have some problems paying its short term obligations.

Compared to an average industry Current Ratio of 1.06, PX is worse placed to pay its short term obligations than its industry peers.
A Quick Ratio of 0.82 indicates that PX may have some problems paying its short term obligations.
Compared to an average industry Quick Ratio of 1.06, PX is worse placed to pay its short term obligations than its industry peers.
Based on the Altman-Z score of 1.57, we must say that PX is in the distress zone and has some risk of bankruptcy.
VS Industry

Debt/Equity (0.74) VS Industry: 48% outperformed.

8.26
0.00

Quick Ratio (0.82) VS Industry: 35% outperformed.

-0.77
5,803.88

Current Ratio (0.82) VS Industry: 33% outperformed.

0.03
5,803.88

Altman-Z (1.57) VS Industry: 65% outperformed.

-100.79
4,363.80

Dividend

Dividend Rating

2

36.03% of the earnings are spent on dividend by PX. This is a low number and sustainable payout ratio.
PX has a Yearly Dividend Yield of 1.07%.
With a Dividend Yield of 1.07, PX pays less dividend than the industry average, which is at 4.57. 91% of the companies listed in the same industry pay a better dividend than PX!

With a Dividend Yield of 1.07, PX pays less dividend than the S&P500 average, which is at 2.55.
PX does not have a reliable dividend history as it only pays dividend since a couple or years.
VS Industry

Dividend Yield (1.07%) VS Industry: 9% outperformed.

0.02
238.91

P10 INC-A9.87

NYSE:PX (3/24/2023, 7:00:00 PM)+0.27 (+2.81%)

After market: 9.87 0 (0%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupDiversified Financials
GICS IndustryCapital Markets
Earnings (Last)03-06 2023-03-06/amc
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners0.43%
Ins Owner Change0%
Market Cap1.16B
Analysts85.33
Price Target15.3 (55.02%)
Dividend
Industry RankSector Rank
Dividend Yield 1.07%
Dividend Growth(5Y)N/A
DP36.03%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-Date03-15 2023-03-15 (0.03)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.97%
Min EPS beat(2)2.68%
Max EPS beat(2)3.25%
EPS beat(4)4
Avg EPS beat(4)3.54%
Min EPS beat(4)2.68%
Max EPS beat(4)4.41%
Revenue beat(2)2
Avg Revenue beat(2)6.78%
Min Revenue beat(2)1.84%
Max Revenue beat(2)11.73%
Revenue beat(4)3
Avg Revenue beat(4)3.6%
Min Revenue beat(4)-2.86%
Max Revenue beat(4)11.73%
PT rev (1m)0%
PT rev (3m)1.12%
EPS NQ rev (1m)-1.31%
EPS NQ rev (3m)-1.1%
EPS NY rev (1m)-5.43%
EPS NY rev (3m)-5.43%
Revenue NQ rev (1m)1.38%
Revenue NQ rev (3m)1.38%
Revenue NY rev (1m)-1.59%
Revenue NY rev (3m)-1.59%
Valuation
Industry RankSector Rank
PE 12.34
Fwd PE 10.4
P/S 5.82
P/FCF 19.18
P/OCF 18.73
P/B 2.94
P/tB N/A
EV/EBITDA 19.68
EPS(TTM)0.8
EY8.11%
EPS(NY)0.95
Fwd EY9.62%
FCF(TTM)0.51
FCFY5.21%
OCF(TTM)0.53
OCFY5.34%
SpS1.69
BVpS3.36
TBVpS-2.27
PEG (NY)0.66
PEG (5Y)0.14
Profitability
Industry RankSector Rank
ROA 3.53%
ROE 7.43%
ROIC 4.74%
ROICexc 4.87%
ROICexgc 44.69%
OM 21.89%
PM 14.72%
GM N/A
ROICexgc(3y)42.01%
ROICexcg growth 3Y-9.49%
ROICexcg growth 5YN/A
ROICexc(3y)3.91%
ROICexc growth 3Y-8%
ROICexc growth 5YN/A
OM growth 3Y-8.45%
OM growth 5YN/A
PM growth 3Y-17.89%
PM growth 5Y-10.64%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF 4.8
Debt/EBITDA 4.09
Cap/Depr 5.24%
Profit Quality 206.27%
Current Ratio 0.82
Quick Ratio 0.82
Altman-Z 1.57
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1.96%
Cap/Depr(5y)1.29%
Profit Quality(3y)261.75%
Profit Quality(5y)238.56%
Growth
EPS 1Y86.26%
EPS 3Y22.13%
EPS 5Y88.94%
EPS growth Q2Q22.22%
EPS Next Y18.63%
EPS Next 2Y19.93%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue growth 1Y31.77%
Revenue growth 3Y64.08%
Revenue growth 5Y115.08%
Revenue growth Q2Q27.86%
Revenue Next Year21.17%
Revenue Next 2Y19.98%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.91%
EBIT growth 3Y50.21%
EBIT growth 5YN/A
EBIT Next Year75.57%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y23.22%
FCF growth 3Y53.1%
FCF growth 5Y125.46%
OCF growth 1Y25.82%
OCF growth 3Y54.22%
OCF growth 5Y126.53%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA